← Leaderboards
Bryan R Haugen
University Of Colorado Denver
$9,253,787
Attributed
$9,920,396
Total exposure
10
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $934.6K · FY2005–23$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$9,920,396 · 10
By mechanism
R01$8,453,498 · 5
RC1$999,914 · 1
M01$466,984 · 4
Top collaborators
- James A Fagin2 shared
- Jeffrey Allen Knauf2 shared
Most similar at University Of Colorado Denver
Same institution · by research overlap
- Dana Sue Hardin$2,621,431
- Thomas Beadnell$69,617
- Madison Mariah King Rose$111,238
- Meghan D Kellett$130,958
- Hannah M Hicks$66,816
Others in their field
Top investigators on “Malignant Neoplasm Of Thyroid”
- David Heimbrook · Leidos Biomedical Research, Inc.$89,819,252
- James A Fagin · Sloan-Kettering Inst Can Research$18,343,965
- Keri Hammel · The Emmes Company, Llc$17,992,237
- Stanley R Hamilton · Johns Hopkins University$17,360,724
- Larry Arthur$15,377,757
- Ignacio I. Wistuba · Ut Southwestern Medical Center$15,303,923
Research focus
Malignant Neoplasm Of ThyroidIn VitroCancer Cell LineMalignant NeoplasmsPathway InteractionsEffective TherapyIn VivoAdvanced Malignant NeoplasmTherapeutic TargetCancer CellGeneticTumorClinical TrialsNeoplasm MetastasisEndocrineTumor GrowthMouse ModelOperative Surgical ProceduresLeadIn Vivo ModelTumor ProgressionClinical ResearchCellsResponse
Grant awards (37)
Chromosomal Instability as a Therapeutic Target in Anaplastic Thyroid Cancer$445,780
R01 · FY2023 · CA · contact PI
Chromosomal Instability as a Therapeutic Target in Anaplastic Thyroid Cancer$445,778
R01 · FY2022 · CA · contact PI
Chromosomal Instability as a Therapeutic Target in Anaplastic Thyroid Cancer$454,878
R01 · FY2021 · CA · contact PI
Chromosomal Instability as a Therapeutic Target in Anaplastic Thyroid Cancer$451,100
R01 · FY2020 · CA · contact PI
Chromosomal Instability as a Therapeutic Target in Anaplastic Thyroid Cancer$464,975
R01 · FY2019 · CA · contact PI
TXNIP as a Key Regulator of Thyroid Cancer Metabolism and Aggressiveness$322,663
R01 · FY2017 · CA · contact PI
TXNIP as a Key Regulator of Thyroid Cancer Metabolism and Aggressiveness$322,663
R01 · FY2016 · CA · contact PI
TXNIP as a Key Regulator of Thyroid Cancer Metabolism and Aggressiveness$322,403
R01 · FY2015 · CA · contact PI
The NFkB-dependent Secretome and Invasion/Angiogenesis in Thyroid Cancer$309,469
R01 · FY2015 · CA · contact PI
TXNIP as a Key Regulator of Thyroid Cancer Metabolism and Aggressiveness$311,725
R01 · FY2014 · CA · contact PI
The NFkB-dependent Secretome and Invasion/Angiogenesis in Thyroid Cancer$300,185
R01 · FY2014 · CA · contact PI
TXNIP as a Key Regulator of Thyroid Cancer Metabolism and Aggressiveness$320,329
R01 · FY2013 · CA · contact PI
The NFkB-dependent Secretome and Invasion/Angiogenesis in Thyroid Cancer$290,901
R01 · FY2013 · CA · contact PI
The NFkB-dependent Secretome and Invasion/Angiogenesis in Thyroid Cancer$309,469
R01 · FY2012 · CA · contact PI
The NFkB-dependent Secretome and Invasion/Angiogenesis in Thyroid Cancer$305,422
R01 · FY2011 · CA · contact PI
A Validated Resource of Thyroid Cancer Cell Lines for Pathway Discovery$499,914
RC1 · FY2010 · CA · contact PI
A Validated Resource of Thyroid Cancer Cell Lines for Pathway Discovery$500,000
RC1 · FY2009 · CA · contact PI
Thiazolidinediones as Thyroid Cancer Therapy$284,732
R01 · FY2009 · CA · contact PI
Thiazolidinediones as Thyroid Cancer Therapy$149,896
R01 · FY2009 · CA · contact PI
Thiazolidinediones as Thyroid Cancer Therapy$284,767
R01 · FY2008 · CA · contact PI
EFCT OF RSTRATION OF EUTHYROIDISM ON ENDOTHELIAL FNCTION IN PTS W/THYROID FAILUR$2,215
M01 · FY2008 · RR · contact PI
Thiazolidinediones as Thyroid Cancer Therapy$284,803
R01 · FY2007 · CA · contact PI
EFCT OF RSTRATION OF EUTHYROIDISM ON ENDOTHELIAL FNCTION IN PTS W/THYROID FAILUR$18,851
M01 · FY2007 · RR · contact PI
Thiazolidinediones as Thyroid Cancer Therapy$293,346
R01 · FY2006 · CA · contact PI
Thiazolidinediones as Thyroid Cancer Therapy$296,218
R01 · FY2005 · CA
ROLE OF RETINOIDS AND RECEPTORS IN THYROTROPE FUNCTION$297,966
R01 · FY2004 · DK
ROLE OF RETINOIDS AND RECEPTORS IN THYROTROPE FUNCTION$298,264
R01 · FY2003 · DK
ROLE OF RETINOIDS AND RECEPTORS IN THYROTROPE FUNCTION$298,541
R01 · FY2002 · DK
METABOLIC DERANGEMENTS IN THYROID DISEASE$190,747
M01 · FY2002 · RR
ROLE OF RETINOIDS AND RECEPTORS IN THYROTROPE FUNCTION$294,718
R01 · FY2001 · DK
METABOLIC DERANGEMENTS IN THYROID DISEASE$190,747
M01 · FY2001 · RR
METABOLIC DERANGEMENTS IN THYROID DISEASE$0
M01 · FY2001 · RR
ROLE OF RETINOIDS AND RECEPTORS IN THYROTROPE FUNCTION$292,507
R01 · FY2000 · DK
METABOLIC DERANGEMENTS IN THYROID DISEASE$32,212
M01 · FY2000 · RR
TAXOL 96 HR INFUSION FOR ANAPLASTIC CARCINOMA OF THE THYROID$32,212
M01 · FY2000 · RR
METABOLIC DERANGEMENTS IN THYROID DISEASE$0
M01 · FY2000 · RR
TAXOL 96 HR INFUSION FOR ANAPLASTIC CARCINOMA OF THE THYROID$0
M01 · FY2000 · RR